Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 

/0 Comments/in , , , , , /by

 

You might also like
MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA Moxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia
asco 2016 atezolizumab data ASCO16 Atezolizumab (Tecentriq©) Data
ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised
Emapalumab FDA approved in adult and paediatric patients with primary hemophagocytic lymphohistiocytosis
Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency CAR-T Axicabtagene ciloleucel FDA approved for relapsed or refractory large B-cell lymphoma
ASCO 2018 nsclc immunotherapy ASCO18 lung cancer pembrolizumab avelumab nivolumab duravalumab ipilimumab osimertinib dacomitinib lorlatinib crizotinib alectinib keytruda KEYNOTE CheckMate JAVELIN IMpower©eraxion / 123RF Stock Photo ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply